Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sudden Neurologic Deterioration after Thrombolysis of Vertebral Artery Occlusion
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
4-004

To illustrate the significance of thrombus migration in the posterior circulation post-tPA administration as well as the importance of adequate access to thrombectomy in the event of clinical neurological deterioration.

Thrombolytic agents such as alteplase (tPA) attain recanalization, improving clinical outcomes in patients with acute ischemic stroke by disrupting and dissolving thrombus. Some recent studies have revealed that thrombus migration following tPA administration may result in harmful perfusion worsening by distal artery occlusion and increase the proportion of the thrombus inaccessibility by endovascular therapy (EVT), particularly in cases of more proximal occlusion of the anterior circulation. However, thrombus migration following thrombolysis in the posterior circulation has not been well-studied. In this case series, we outline two cases that represent posterior circulation, vertebral to basilar thrombus migration following tPA administration.

We searched the Quality Improvement and Clinical Research (QuICR) database from April 2015 – March 2018 to identify cases of isolated vertebral occlusion. This database collects data for all ischemic stroke patients treated with alteplase (tPA and TNK) or endovascular treatment in the province of Alberta.

From all the patients to have received alteplase or endovascular therapy from April 2015 – March 2018 in the province of Alberta, Canada, we identified 7 cases of isolated intra or extracranial vertebral occlusion treated with tPA. Of these 7 cases, 2 cases went on to receive endovascular therapy following tPA administration due to worsening clinical status of the patient and imaging revealing migration of the thrombus.

Strokes that initially present as a thrombus originating in the vertebral arteries may evolve post tPA administration to more distal and serious vascular territories through thrombus migration. Transferring the patient to a tertiary stroke center with rapid access to endovascular therapy options is key in attempting to treat patients that experience rapid deterioration secondary to thrombus migration. 

Authors/Disclosures
Sina Marzoughi, MD
PRESENTER
Dr. Marzoughi has nothing to disclose.
Ankur Banerjee, MD (University of Alberta) No disclosure on file
No disclosure on file
No disclosure on file
Charlotte Zerna No disclosure on file
No disclosure on file
Bijoy Menon, MD (University of Calgary) Dr. Menon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Menon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Menon has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Circle NVI. Dr. Menon has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke VIN. Dr. Menon has stock in Circle NVI.
Andrew M. Demchuk, MD (Foothills Hospital/Calgary Stroke Program) Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care.